Given the complexity of HRD biomarkers, key assay features include the selection of HRR genes (BRCA1, BRCA2, PALB2, RAD51C, RAD51D), definitions of genomic scars (LOH, TAI, LST), mutational signatures analyzed, use of comparator samples, and tumor-specific HRD score calculations. This evidence concerns the gene BRCA1 and neoplasm.